SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its companion diagnostic collaboration with AstraZeneca and Merck (known as MSD outside the US and Canada). Under the expanded collaboration, the companies will use BRACAnalysis CDx® to identify germline BRCA mutations in men who …